VEGF Family GWAS Signals and Cerebrovascular-Neuronal Coupling in AD Hippocampus

Theorist position for analysis a7f528aa-20c4-409d-a8c3-e2662850e63d: VEGF Family GWAS Signals and Cerebrovascular-Neuronal Coupling in AD Hippocampus

Source basis: Association of ten VEGF family genes with Alzheimer's disease endophenotypes at single cell level (Alzheimer's & Dementia, 2025, DOI 10.1002/alz.14419). The stored gap context says: VEGF family single-cell GWAS analysis identified associations with AD endophenotypes; the causal mechanism linking VEGF variants to hippocampal vascular-neuronal coupling was highlighted as requiring investigation.

Primary hypothesis: VEGF-family genetic control of vascular-neuronal coupling in vulnerable hippocampal regions is not merely an associated signature; it is a testable mechanism that can explain the open question: How do VEGF family gene variants identified by single-cell GWAS analysis alter cerebrovascular-neuronal coupling specifically in the AD hippocampus, and can spatial transcriptomics resolve whether VEGF-driven vascular dysfunction precedes or follows amyloid deposition in vulnerable hippocampal subfields?

Three candidate claims should be carried forward. First, the strongest causal signal should appear in the cell type or tissue compartment named by the question, not only in bulk disease contrasts. Second, perturbing the axis should shift a proximal molecular phenotype before it shifts a late pathology phenotype, which would help separate cause from consequence. Third, the relevant readout should be stratified by VEGF, GWAS, VEGF-, because collapsing across those terms would erase the mechanism the analysis is trying to test.

The priority experiment is spatial transcriptomics plus vascular imaging ordered against amyloid and tau burden across hippocampal subfields. A positive result would require concordance across human observational data, disease-relevant cellular models, and at least one perturbation that moves the predicted proximal readout in the expected direction.

Skeptic critique for analysis a7f528aa-20c4-409d-a8c3-e2662850e63d: VEGF Family GWAS Signals and Cerebrovascular-Neuronal Coupling in AD Hippocampus

The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Association of ten VEGF family genes with Alzheimer's disease endophenotypes at single cell level could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: vascular changes may be secondary to neurodegeneration rather than upstream drivers.

The debate should reject any claim that only restates the title. To survive, the hypothesis must specify a direction of effect, the cell state in which it is expected, and a falsifier. For this analysis, a decisive falsifier would be failure to observe the predicted proximal change after perturbing VEGF-family genetic control of vascular-neuronal coupling in vulnerable hippocampal regions in the disease-relevant model, even when technical power and cell-state annotation are adequate.

The strongest alternative explanation is that VEGF, GWAS, VEGF- mark disease severity rather than mechanism. A second alternative is that the source paper's unresolved question reflects measurement granularity: the right assay may not yet separate the causal cell state from a reactive bystander state. The study design therefore needs negative controls, genotype or pathology stratification, and replication in an independent cohort.

Domain expert assessment for analysis a7f528aa-20c4-409d-a8c3-e2662850e63d: VEGF Family GWAS Signals and Cerebrovascular-Neuronal Coupling in AD Hippocampus

The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test VEGF-family genetic control of vascular-neuronal coupling in vulnerable hippocampal regions in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point.

For model systems, prioritize human iPSC-derived disease-relevant cells, co-culture or organoid systems only when the question explicitly requires cross-cell interaction, and mouse models only for organism-level timing or NMJ/vascular phenotypes. Biomarkers should be proximal to mechanism: transcriptional module activity, protein localization, lipid or RNA-modification state, spatial vascular coupling, or motor-unit integrity depending on the gap.

The development risk is moderate. The question is specific enough to generate falsifiable work, and it is anchored to Association of ten VEGF family genes with Alzheimer's disease endophenotypes at single cell level. The risk is that therapeutic tractability may lag mechanistic clarity: even if VEGF-family genetic control of vascular-neuronal coupling in vulnerable hippocampal regions is causal, the safest intervention point may be an upstream regulator, a cell-state transition, or a biomarker-guided patient subset rather than the named entity itself.